ASND – ascendis pharma a/s - american depositary shares (US:NASDAQ)
Stock Stats
News
Ascendis Pharma gains amid takeover speculation [Seeking Alpha]
Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at Stifel Nicolaus from $254.00 to $256.00. They now have a "buy" rating on the stock.
Former Novo Nordisk Executive Jesper Høiland Joins Alva Therapeutics' Board of Directors
Ascendis Pharma (ASND): Is There More Upside in the Valuation After Recent Momentum? [Yahoo! Finance]
How the FDA's TransCon CNP Review Delay at Ascendis Pharma (ASND) Has Changed Its Investment Story [Yahoo! Finance]
Form 6-K Ascendis Pharma A/S For: Dec 10
Form 144 Ascendis Pharma A/S Filed by: JENSEN MICHAEL WOLFF
Form 144 Ascendis Pharma A/S Filed by: MIKKELSEN JAN MOLLER
Form 144 Ascendis Pharma A/S Filed by: SPROGOE KENNETT
Form 144 Ascendis Pharma A/S Filed by: JENSEN FLEMMING STEEN
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.